Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LEVOMILNACIPRAN

LEVOMILNACIPRAN

Standard Dose
80MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview LEVOMILNACIPRAN is listed in Drugs@FDA under application 210857 (ANDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LEVOMILNACIPRAN Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 80MG Sponsor ZYDUS PHARMS USA INC Submission history Latest submission status date: 2023-01-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview LEVOMILNACIPRAN is listed in Drugs@FDA under application 210857 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient LEVOMILNACIPRAN Form and strength CAPSULE, EXTENDED RELEASE;ORAL - 80MG Sponsor ZYDUS PHARMS USA INC Submission history Latest submission status date: 2023-01-12 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.